Skip to content

SOHO Egypt 2025 debuts with 2-day meeting in Cairo
FDA approves ziftomenib for relapsed or refractory NMP1-mutated AML
FDA grants 510(k) clearance to multiple myeloma diagnostic platform
IDP-023 demonstrates good safety, efficacy in relapsed or refractory myeloma
SOHO Young Investigator spotlight: Meet Maha Hameed, MD

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Rami Komrokji, MD

Cellular Therapy

Rami Komrokji, MD

Leukemia

Rami Komrokji, MD

Lymphoma

Rami Komrokji, MD

Multiple Myeloma

Rami Komrokji, MD

Myelodysplastic Syndromes

Rami Komrokji, MD

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

November 16, 2025

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

SOHO Insider Rami Komrokji, MD

Rami-Komrokji

Rami Komrokji, MD

by Leah Sherwood
October 16, 2024
0 Comments
Less than a minute
88 Views
1 year ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

SOHO Egypt attendees

Ambassador Program, News, Society Updates

SOHO Egypt 2025 debuts with 2-day meeting in Cairo

November 14, 2025

Leukemia News

FDA approves ziftomenib for relapsed or refractory NMP1-mutated AML

November 14, 2025

FDA Green light

Multiple Myeloma

FDA grants 510(k) clearance to multiple myeloma diagnostic platform

November 13, 2025

Multiple Myeloma. Multiple Myeloma disease blood test inmedical laboratory

SITC 2025, Multiple Myeloma

IDP-023 demonstrates good safety, efficacy in relapsed or refractory

November 12, 2025

Maha Hameed

Multiple Myeloma, News, Society Updates, Young Investigator Program

SOHO Young Investigator spotlight: Meet Maha Hameed, MD

November 11, 2025

SITC 2025, Leukemia, Acute Lymphoblastic Leukemia, News

Natural killer T-cells show promise for ‘off-the-shelf’ cancer immunotherapy

November 10, 2025

Top Categories

Cellular Therapy

13

Leukemia

66

Lymphoma

58

Multiple Myeloma

54

Myelodysplastic Syndromes

23

Myeloproliferative Neoplasms

12

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Rami Komrokji, MD

Cellular Therapy

Rami Komrokji, MD

Leukemia

Rami Komrokji, MD

Lymphoma

Rami Komrokji, MD

Multiple Myeloma

Rami Komrokji, MD

Myelodysplastic Syndromes

Rami Komrokji, MD

Myeloproliferative Neoplasms

Subscribe

Recent Posts

SOHO Egypt attendees

SOHO Egypt 2025 debuts with 2-day meeting in Cairo

FDA approves ziftomenib for relapsed or refractory NMP1-mutated AML

FDA Green light

FDA grants 510(k) clearance to multiple myeloma diagnostic platform

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.